A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828

Hypertension Clinical Trial

Official title:

An Open-label, Randomized, Fasted, Single-dose, 2-sequence, 4-period, Replicate Crossover Study to Compare the Pharmacokinetic and Safety Between Administration of CKD-828 20/2.5mg and Administration of D064, D701 in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05834595
• Other study ID #: A30_19BE2305
• Status: Completed
• Phase: Phase 1
• Start date: May 2, 2023
• Est. completion date: July 26, 2023

Study information

• Verified date: April 2023
• Source: Chong Kun Dang Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A clinical trial to compare the pharmacokinetic and safety of CKD-828

Description:

An open-label, randomized, fasted, single-dose, 2-sequence, 4-period, replicate crossover study to compare the pharmacokinetic characteristics and safety between administration of CKD-828 20/2.5mg and administration of D064, D701 in healthy adults

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: July 26, 2023
• Est. primary completion date: July 18, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Healthy adult aged = 19 at screening

2. Body mass index (BMI) of 17.5 kg/m2 or more and less than 30.5kg/m2 and Body weight = 55kg

3. Those who do not have congenital or chronic diseases and have no pathological symptoms or findings as a result of medical examination

4. A person who is deemed suitable as a subject as a result of screening such as clinical laboratory examination (hematology, blood chemistry, urinalysis, serological tests, etc.), vital signs, electrocardiogram examination, etc.

5. A person who has received a sufficient explanation of the purpose and contents of the clinical trial and has agreed in writing voluntarily to participate in the clinical trial

6. A person who has agreed to use appropriate contraception and not donate sperm or eggs until 14 days after the first administration of the drug and the last administration of the drug

7. Those who have the ability and willingness to participate during the entire study period

Exclusion Criteria:

1. A history of clinically significant blood, renal, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, psychiatric, neurological, or immune disease (except for simple dental history of calculus, impacted teeth, wisdom teeth, etc.) or evidence on who has

2. Those with a history of gastrointestinal diseases or surgery (expect simple appendicectomy, hernia surgery, and tooth extraction surgery) that may affect drug absorption ruler

3. A person who shows the following values as a result of conducting a clinical laboratory test

• ALT or AST > 2 times the upper limit of the normal range

4. Smokers who smoked more than 20 cigarettes a day within 6 months of screening

5. Those who have taken other investigational product or bioequivalence investigational product within 6 months before the first administration of the investigational product

6. Those who meet the following as a result of measuring vital signs at screening

• Those who have a systolic blood pressure of less than 90 mmHg or more than 140 mmHg or a diastolic blood pressure of less than 60 mmHg or more than 90 mmHg in the sitting position

• Severe bradycardia (less than 50 beats/min)

7. Those with a history of regular alcohol intake within 1 month of screening

• More than 14 drinks/week for women

• More than 21 drinks/week for men

8. A person who has taken a drug known to significantly induce or inhibit drug metabolizing enzymes within 30 days before the first administration of investigational product

9. Those who have taken prescription or non-prescription drugs within 10 days prior to the first administration of investigational product

10. Those who have donated whole blood within 2 months before the first administration of the investigational product, donated component blood within 1 month, received blood transfusion within 1 month, or have plans for the trial during the clinical trial period

11. Those who are judged by the principal investigator (or the person in charge of the test who has been delegated) for reason other than the above selection/exclusion criteria and are judged unsuitable for participation in the study

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• CKD-828, D064, D701
QD, PO

Locations

Country	Name	City	State
Korea, Republic of	Central hospital	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCt of CKD-828	Area under the concentration-time curve time zero to time	Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72 hours
Primary	Cmax of CKD-828	Maximum plasma concentration of the drug	Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72 hours